- Home
- ACB vs ARCT Comparison
ACB vs ARCT Comparison
Compare ACB & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- ARCT
- Stock Information
- Founded
- ACB 2013
- ARCT 2013
- Country
- ACB Canada
- ARCT United States
- Employees
- ACB N/A
- ARCT N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- ARCT Health Care
- Exchange
- ACB Nasdaq
- ARCT Nasdaq
- Market Cap
- ACB 286.5M
- ARCT 298.3M
- IPO Year
- ACB N/A
- ARCT N/A
- Fundamental
- Price
- ACB $5.24
- ARCT $12.92
- Analyst Decision
- ACB Hold
- ARCT Strong Buy
- Analyst Count
- ACB 1
- ARCT 8
- Target Price
- ACB N/A
- ARCT $52.33
- AVG Volume (30 Days)
- ACB 804.2K
- ARCT 450.8K
- Earning Date
- ACB 06-20-2025
- ARCT 05-12-2025
- Dividend Yield
- ACB N/A
- ARCT N/A
- EPS Growth
- ACB N/A
- ARCT N/A
- EPS
- ACB 0.07
- ARCT N/A
- Revenue
- ACB $222,964,332.00
- ARCT $143,680,000.00
- Revenue This Year
- ACB $27.84
- ARCT N/A
- Revenue Next Year
- ACB $11.50
- ARCT $42.36
- P/E Ratio
- ACB $83.09
- ARCT N/A
- Revenue Growth
- ACB 20.72
- ARCT 15.38
- 52 Week Low
- ACB $3.42
- ARCT $8.04
- 52 Week High
- ACB $7.20
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- ACB 55.42
- ARCT 59.32
- Support Level
- ACB $5.37
- ARCT $11.51
- Resistance Level
- ACB $5.61
- ARCT $13.00
- Average True Range (ATR)
- ACB 0.25
- ARCT 0.99
- MACD
- ACB -0.00
- ARCT 0.12
- Stochastic Oscillator
- ACB 44.32
- ARCT 79.76
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.